Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-249170621fe2e34bc97c331b03b5b5b0"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-249170621fe2e34bc97c331b03b5b5b0"/>
<resource>
<Composition>
<id value="composition-en-249170621fe2e34bc97c331b03b5b5b0"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-249170621fe2e34bc97c331b03b5b5b0"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-249170621fe2e34bc97c331b03b5b5b0</b></p><a name="composition-en-249170621fe2e34bc97c331b03b5b5b0"> </a><a name="hccomposition-en-249170621fe2e34bc97c331b03b5b5b0"> </a><a name="composition-en-249170621fe2e34bc97c331b03b5b5b0-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/18/1335/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - poteligeo</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/18/1335/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp249170621fe2e34bc97c331b03b5b5b0"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - poteligeo"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What POTELIGEO is and what it is used for</li><li>What you need to know before you use POTELIGEO</li><li>How POTELIGEO is given</li><li>Possible side effects</li><li>How to store POTELIGEO</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What poteligeo is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What poteligeo is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>POTELIGEO contains the active substance mogamulizumab, which belongs to a group of medicines called monoclonal antibodies. Mogamulizumab targets cancer cells which are then destroyed by the immune system (the body s defence).</p><p>This medicine is used to treat adults with mycosis fungoides and S zary syndrome, which are types of cancers called cutaneous T-cell lymphomas. The medicine is for use in patients who have received at least one medicine given by mouth or by injection.</p></div>
</text>
</section>
<section>
<title
value="2. What you need to know before you take poteligeo"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take poteligeo"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not use POTELIGEO:</p><ul><li>if you are allergic to mogamulizumab or any of the other ingredients of this medicine (listed in section 6).</li></ul><p>Warnings and precautions</p><p>Talk to your doctor or nurse before using POTELIGEO if you:</p><ul><li>ever had a severe skin reaction with this medicine.</li><li>ever had an infusion reaction with this medicine (possible symptoms of an infusion reaction are listed in section 4).</li><li>have human immunodeficiency virus (HIV), herpes, cytomegalovirus (CMV), or hepatitis B or C infection, or other on-going infections.</li><li>have had or plan to have a stem cell transplant, either using your own cells or a donor s.</li><li>have had tumour lysis syndrome (a complication involving the destruction of cancer cells) after a previous treatment.</li><li>have heart problems.</li></ul><p>Tell the person giving you the infusion or get medical help straight away if you experience a reaction during or after any POTELIGEO infusion.</p><p>Tell your doctor immediately if you experience any of the serious side effects listed in Section 4 after starting POTELIGEO treatment.</p><p>Other medicines and POTELIGEO Tell your doctor if you are taking, have recently taken,or might take any other medicines.</p><p>Children and adolescents This medicine should not be used in children and adolescents below 18 years of age.</p><p>Pregnancy and breast-feeding The effects of POTELIGEO in pregnancy and breast-feeding are not known. Due to the mechanism of action of the medicine, it may harm your baby if it is administered when you are pregnant or breast- feeding.</p><p>If you can get pregnant, you will need to use effective contraception during and for at least six months after receiving this treatment.</p><p>If you are breast-feeding, you should discuss with your doctor whether you can breast-feed during or after treatment with POTELIGEO.</p><p>You must tell your doctor or nurse if you are pregnant, breast-feeding, think you may be pregnant, or are planning to have a baby.</p><p>Driving and using machines POTELIGEO is unlikely to affect your ability to drive and use machines. However, the medicine can cause tiredness in some people, so take particular care when driving and using machines until you are certain that this medicine does not affect you.</p><p>POTELIGEO contains sodium This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially sodium-free .</p></div>
</text>
</section>
<section>
<title value="3. How to take poteligeo"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take poteligeo"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>The amount of POTELIGEO you will receive is calculated by your doctor based on your body weight.<br/>The recommended dose is 1mg POTELIGEO for each kg of body weight.</p><p>POTELIGEO will be given to you through a vein (intravenous infusion) over at least 60 minutes. To start with, the infusions will be given once a week for the first 5 doses, then once every 2 weeks. Treatment should be continued unless you get serious side effects or the cutaneous T-cell lymphoma starts to get worse.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Serious side effects</p><p>Tell your doctor or nurse or get medical help immediately if you have any of the following signs and symptoms after starting POTELIGEO:</p><p>Very common side effects (may affect more than 1 in 10 people):</p><ul><li><p>chills, nausea or vomiting, headache, wheezing, itching, flushing, rash, dizziness or feeling faint, difficulty breathing and fever, which may be signs of an infusion reaction. If this happens, the infusion may need to be stopped and you may require additional treatment. When the symptoms go away, POTELIGEO can normally continue to be given, but more slowly. Your doctor may stop POTELIGEO treatment if your reaction is severe.</p></li><li><p>signs of infection, which may include a fever, sweats or chills, flu-like symptoms, sore throat or difficulty swallowing, cough, shortness of breath, stomach pain, nausea or vomiting, diarrhoea and feeling very unwell.</p></li><li><p>skin rash (which may become severe), or sore mouth. In some people receiving POTELIGEO for other types of cancers, skin pain/burning sensation, itching, skin blisters/peeling, ulcers in the mouth or on the lips or genitals occurred, which are possible signs of a severe skin reaction, such as Stevens-Johnson syndrome or toxic epidermal necrolysis (which affected up to 1 in people).<br/>Uncommon side effects (may affect up to 1 in 100 people):</p></li><li><p>fever, chills, nausea, vomiting, confusion, shortness of breath, seizures, irregular heartbeat, dark or cloudy urine, unusual tiredness and/or muscle or joint pain. The destruction of cancer cells and the body s reaction to it can very occasionally lead to a problem called tumour lysis syndrome.</p></li><li><p>chest pain, shortness of breath, fast or slow heartbeat, sweating, dizziness, nausea or vomiting, weakness, feeling faint and feeling unwell. Although unlikely to be caused by this medicine, these may be signs of a heart disorder. Not known (frequency cannot be estimated from the available data):</p></li><li><p>if you go on to have a stem cell transplant, it is possible that you could then develop complications (graft versus host disease) that are difficult to manage. Symptoms may include skin rashes or blistering, nausea or diarrhoea that doesn t go away, stomach pain or vomiting, joint pain or stiffness, dry or irritated eyes or blurred vision, mouth sores, irritation or pain, a cough that does not go away or difficulty breathing, sensitive genitals, jaundice (turning yellow), dark urine, and any swelling.</p></li></ul><p>Other side effects</p><p>Talk to your doctor if you get any other side effects. These can include:</p><p>Very common side effects (may affect more than 1 in 10 people):</p><ul><li>Lack of energy (fatigue)</li><li>Constipation</li><li>Swollen legs or ankles</li><li>Headache</li></ul><p>Common side effects (may affect up to 1 in 10 people):</p><ul><li>Anaemia (reduced red blood cells)</li><li>Reduced blood platelets (thrombocytopenia)</li><li>Reduced white blood cells (neutropenia and leucopenia) or reduced lymphocytes</li><li>Blood tests showing raised liver enzyme levels</li><li>Underactive thyroid</li></ul><p>Uncommon side effects (may affect up to 1 in 100 people)</p><ul><li>Inflammation of the liver (hepatitis)</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store poteligeo"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store poteligeo"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and the vial after EXP . The expiry date refers to the last day of that month.</p><p>Unopened vial: Store in a refrigerator (2 C - 8 C). Do not freeze.</p><p>Store in the original carton in order to protect from light</p><p>Reconstituted/diluted solution: Use immediately or store in a refrigerator (2 C - 8 C) and use within 24 hours.</p><p>Do not use this medicine if you notice signs of deterioration, such as particulate matter or discolouration.</p><p>Do not throw away any medicines via wastewater or household waste. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What POTELIGEO contains</p><ul><li>Each vial contains 20 mg of mogamulizumab in 5 mL of concentrate, corresponding to 4 mg/mL.</li><li>The other excipients are citric acid monohydrate, glycine, polysorbate 80, sodium hydroxide, hydrochloric acid, and water for injections. See section 2 POTELIGEO contains sodium .</li></ul><p>What POTELIGEO looks like and contents of the pack POTELIGEO is a clear, colourless solution. The pack contains a glass vial containing 5 mL concentrate for solution for infusion.</p><p>Marketing Authorisation Holder Kyowa Kirin Holdings B.V. Bloemlaan 2 2132NP Hoofddorp Netherlands</p><p>Manufacturer<br/>allphamed PHARBIL Arzneimittel GmbH Hildebrandstr. 10-37081 G ttingen Germany</p><p>This leaflet was last revised in <{MM/YYYY}><{month YYYY}>.</p><p>Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp249170621fe2e34bc97c331b03b5b5b0"/>
<resource>
<MedicinalProductDefinition>
<id value="mp249170621fe2e34bc97c331b03b5b5b0"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp249170621fe2e34bc97c331b03b5b5b0"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp249170621fe2e34bc97c331b03b5b5b0</b></p><a name="mp249170621fe2e34bc97c331b03b5b5b0"> </a><a name="hcmp249170621fe2e34bc97c331b03b5b5b0"> </a><a name="mp249170621fe2e34bc97c331b03b5b5b0-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/18/1335/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: POTELIGEO 4 mg/mL concentrate for solution for infusion</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/18/1335/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName
value="POTELIGEO 4 mg/mL concentrate for solution for infusion"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
